Neuroendocrine Tumors: all 682 studies

Page 3 of 7. Open to participants first (163), then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted
• FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasTerminatedNCT03042780Phase 2Results posted
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
• Phase 2 Study of ONC201 in Neuroendocrine TumorsCompletedNCT03034200Phase 2Results posted
• Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)CompletedNCT02955069Phase 2Results posted
• A Study of Pembrolizumab in Patients With Neuroendocrine TumorsCompletedNCT02939651Phase 2Results posted
• PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersCompletedNCT02936323Phase 1/2Results posted
• Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
• Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 MicrospheresTerminatedNCT02859064Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.CompletedNCT02698410Phase 2Results posted
• Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursTerminatedNCT02683941Phase 3Results posted
• Lenvatinib Efficacy in Metastatic Neuroendocrine TumorsCompletedNCT02678780Phase 2Results posted
• Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mgCompletedNCT02651987Phase 2Results posted
• Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine TumorsCompletedNCT02609737Not applicableResults posted
• Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETsTerminatedNCT02592707Phase 1/2Results posted
• Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT02575300Phase 2Results posted
• RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)CompletedNCT02489903Phase 2Results posted
• Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine TumorsCompletedNCT02441062Phase 2Results posted
• Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut OriginCompletedNCT02420691Phase 2Results posted
• Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung CancerCompletedNCT02402920Phase 1Results posted
• A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic TumoursCompletedNCT02402062Phase 2Results posted
• Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02399215Phase 2Results posted
• Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
• Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)CompletedNCT02299089Phase 2Results posted
• A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)TerminatedNCT02288377Phase 2/3Results posted
• The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine TumorsCompletedNCT02282059Results posted
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney CancerTerminatedNCT02273752Phase 2Results posted
• OPALINE : A Study Of Morbidity And Mortality At 2 YearsCompletedNCT02264665Results posted
• Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine TumorsCompletedNCT02259725Phase 2Results posted
• Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine TumorCompletedNCT02246127Phase 3Results posted
• Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETCompletedNCT02231762Phase 2Results posted
• GA-68 DOTA-TOC of Somatostatin Positive MalignanciesTerminatedNCT02177773Phase 1/2Results posted
• 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1/2Results posted
• A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated BiomarkersCompletedNCT02132468Phase 2Results posted
• Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
• Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours PatientsCompletedNCT02075606Phase 4Results posted
• Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With SurgeryTerminatedNCT02031536Phase 2Results posted
• Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid TumorsCompletedNCT01970540Phase 1Results posted
• Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine TumorsCompletedNCT01967537Phase 2Results posted
• Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CTCompletedNCT01869725Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsActive, not recruitingNCT01841736Phase 2Results posted
• Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored StudiesCompletedNCT01794793Phase 4Results posted
• VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine TumorsTerminatedNCT01784861Phase 1/2Results posted
• Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine CarcinomasCompletedNCT01744249Phase 2/3Results posted
• Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine TumorsTerminatedNCT01719861Phase 2Results posted
• Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine TumorsCompletedNCT01678664Phase 2Results posted
• BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.CompletedNCT01658436Phase 2Results posted
• Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsTerminatedNCT01628913Phase 2Results posted
• Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid TumorsCompletedNCT01619865Phase 1/2Results posted
• An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)CompletedNCT01595009Phase 4Results posted
• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedNCT01578239Phase 3Results posted
• A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01525550Phase 4Results posted
• Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine TumorsCompletedNCT01525082Phase 2Results posted
• Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)CompletedNCT01524783Phase 3Results posted
• Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsCompletedNCT01466036Phase 2Results posted
• Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By SurgeryCompletedNCT01465659Phase 1/2Results posted
• 68Ga-DOTATATE PET Scan in Neuroendocrine CancerCompletedNCT01396382Phase 2Results posted
• Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNETTerminatedNCT01374451Phase 2Results posted
• RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4Results posted
• Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver MetastasesCompletedNCT01290536Phase 2Results posted
• Pazopanib as Single Agent in Advanced NETsCompletedNCT01280201Phase 2Results posted
• Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)CompletedNCT01253161Phase 2Results posted
• Study of Everolimus (RAD001) in Combination With LenalidomideCompletedNCT01218555Phase 1Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT01169649Phase 2Results posted
• Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsCompletedNCT01121562Phase 2Results posted
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid TumorsTerminatedNCT01115803Phase 1Results posted
• AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT01024387Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Study of Panobinostat in Patients With Neuroendocrine TumorsTerminatedNCT00985946Phase 2Results posted
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With ChemotherapyCompletedNCT00965250Phase 2Results posted
• A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsTerminatedNCT00947167Phase 2Results posted
• Capecitabine and Temozolomide for Neuroendocrine CancersCompletedNCT00869050Phase 2Results posted
• RAD001 and Erlotinib in Patients With Neuroendocrine TumorsTerminatedNCT00843531Phase 2Results posted
• A Study of Cixutumumab (IMC-A12) in Islet Cell CancerCompletedNCT00781911Phase 2Results posted
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
• Somatuline Autogel Preference and Health Economy StudyCompletedNCT00681187Phase 4Results posted
• Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the CervixTerminatedNCT00626561Phase 2Results posted
• Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)CompletedNCT00610129Phase 2Results posted
• Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine TumorsCompletedNCT00605566Phase 2Results posted
• RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT00576680Phase 1/2Results posted
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorActive, not recruitingNCT00569127Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsCompletedNCT00510068Phase 3Results posted
• Lithium for Low-Grade Neuroendocrine TumorsCompletedNCT00501540Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Phase II Study of Sunitinib Malate Following Hepatic Artery EmbolizationCompletedNCT00434109Phase 2Results posted
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
• AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedNCT00427349Phase 2Results posted
• Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine TumorsCompletedNCT00398320Phase 2Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsTerminatedNCT00227617Phase 2/3Results posted
• Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the MidgutCompletedNCT00171873Phase 3Results posted
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00131911Phase 2Results posted
• A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in GermanyCompletedNCT07653126
• Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudyActive, not recruitingNCT07534371
• A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsActive, not recruitingNCT07129252Phase 1/2
• Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic CancersActive, not recruitingNCT07118176Phase 1
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenActive, not recruitingNCT07087054Phase 3
• Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor PatientsTerminatedNCT07012330Phase 2
• Correlation Between Body Composition and Pathologic Grade/Prognosis in GEP-NENs: A Retrospective StudyCompletedNCT06983106

← Neuroendocrine Tumors overview